Schrodinger, INC 10-Q quarterly reports

Schrodinger, Inc. reported a 54% revenue increase to $54.3 million in Q3 2025 and a narrowed net loss, driven by strong drug discovery and software growth, despite discontinuing a key clinical program.

Schrodinger, Inc. reported a 16% increase in total revenues for Q2 2025, narrowing its net loss and achieving positive operating cash flow, driven by strong software growth and a significant upfront payment from a new drug discovery collaboration.

Schrdinger, Inc. announces a 63% increase in total revenue for Q1 2025, fueled by growth in both its software and drug discovery segments.

Schrödinger Inc. experienced a revenue decrease in Q3 2024, primarily due to a decline in drug discovery revenue, while software revenue showed modest growth.

Schrdinger, Inc. announced its second quarter 2024 financial results, highlighting a 35% increase in total revenue compared to the same period last year.

Schrodinger Inc. experienced a significant decrease in revenue during the first quarter of 2024, primarily due to a decline in drug discovery revenue, while software revenue saw a modest increase.